Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cartesian Therapeutics, Inc.

http://www.cartesiantherapeutics.com

Latest From Cartesian Therapeutics, Inc.

Scrip Asks...What Does 2022 Hold For Biopharma? Part 3: Technology And Science

Many industry leaders expect broad progress in the field of RNA technologies following the rapid and successful roll-out of mRNA vaccines against COVID-19 last year. Genetic medicines of various types, emerging platforms for tackling previously “undruggable” targets and the microbiome were among other areas singled out as areas to watch in 2022.

Scrip Asks Platform Technologies

Pandemic Perspectives: What’s The New Normal For The Business Of Biopharma?

In Part 2 of Scrip’s roundtable, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors discuss how the pandemic brought in new investors and triggered strategic shifts for the biopharma industry. 

Coronavirus COVID-19 Business Strategies

Pandemic Perspectives: R&D Lessons Learned From The COVID Year

The ways companies found to move forward during the challenging year also offer opportunities for industry to improve. During a roundtable discussion with Scrip, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors weighed in on the adaptations they made and what changes they’ll stick with. 

Coronavirus COVID-19 Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
UsernamePublicRestriction

Register